Paul Farkas, DMD Dentist - Dental Public Health Medicare: Not Enrolled in Medicare Practice Location: Fci Loretto, Loretto, PA 15940 Phone: 814-471-1449 |
News Archive
New year, new face and new brand for Bedfont as Jason Smith, new managing director, is shaking things up for the 40 year old company.
Early testing of an experimental human monoclonal antibody showed a striking benefit in patients with advanced melanoma, say researchers at The University of Texas M. D. Anderson Cancer Center, who presented their findings at the annual meeting of the American Society of Clinical Oncology.
Published in the journal PLOS ONE, the study showed that tackling unhealthy lifestyle factors would provide the greatest benefit in increasing life expectancy among those with SMI.
Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).
Myc cancer gene empowers tumor cells to relentlessly divide but simultaneously, provokes a cell suicide process called apoptosis. Myc controls cells by commanding the expression of every tenth of the genes in the nucleus of a tumor cell. However, in spite of more than two decades of intense research, no Myc motivated killer genes have been found.
› Verified 9 days ago